Back to News
Nov 17, 2025 8:10 AM

Angiex Completes Financings Totaling $31 Million to Advance Phase 1 Dose Escalation of Nuclear-Delivered ADC AGX101 in Patients with Advanced Solid Tumors

CAMBRIDGE, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Angiex Inc., a developer of Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapies for solid cancers, today announced the completion of financings totaling $31 million, with participation from new and existing investors. The proceeds are being used to advance AGX101, a first-in-class TM4SF1-directed ND-ADC, through the dose-escalation portion of the Phase 1 clinical trial, which is designed to assess safety, tolerability and preliminary clinical activity.

"Angiex is very pleased with the strong investor support the company has received from both insiders and new investors, and we are grateful for their support of our shared mission," said Paul Jaminet, Ph.D., Angiex's founder and chief executive officer. "In addition to progressing AGX101 through key endpoints of the Phase 1 clinical trial, these funds enable Angiex to refine its development strategy by further evaluating AGX101 in selected tumor types and in combination with immune checkpoint inhibitors."

Paulson Investment Company, LLC acted as placement agent for an equity offering of $16 million.

About AGX101's Phase 1 Clinical TrialThe Phase 1 study is an open-label, dose-escalation and expansion study designed to assess the safety, pharmacokinetics (PK), pharmacodynamics ...